Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ADAP

Adaptimmune Therapeutics Plc ADR

Apr 19 • 04:00PM ET

0.9767

Dollar change +0.0783
Percentage change 8.72	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	11.90%	Shs Outstand	227.17M	Perf Week	-15.80%
Market Cap	221.88M	Forward P/E	-	EPS next Y	-0.59	Insider Trans	-0.61%	Shs Float	200.15M	Perf Month	-26.56%
Income	-114.08M	PEG	-	EPS next Q	-0.15	Inst Own	62.38%	Short Float	1.60%	Perf Quarter	39.01%
Sales	60.69M	P/S	3.66	EPS this Y	-467.56%	Inst Trans	-0.50%	Short Ratio	1.61	Perf Half Y	66.45%
Book/sh	0.17	P/B	5.62	EPS next Y	-15.85%	ROA	-37.31%	Short Interest	3.20M	Perf Year	-35.32%
Cash/sh	0.65	P/C	1.51	EPS next 5Y	1.00%	ROE	-187.96%	52W Range	0.42 - 2.05	Perf YTD	23.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.30%	ROI	-192.17%	52W High	-52.36%	Beta	2.50
Dividend TTM	-	Quick Ratio	2.85	Sales past 5Y	134.88%	Gross Margin	83.77%	52W Low	132.55%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.85	EPS Y/Y TTM	48.98%	Oper. Margin	-250.53%	RSI (14)	32.27	Volatility	13.75% 9.64%
Employees	449	Debt/Eq	0.64	Sales Y/Y TTM	123.93%	Profit Margin	-187.98%	Recom	2.14	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	-18.55%	Payout	-	Rel Volume	0.74	Prev Close	0.90
Sales Surprise	-99.11%	EPS Surprise	75.76%	Sales Q/Q	-97.90%	Earnings	Mar 06 BMO	Avg Volume	1.99M	Price	0.98
SMA20	-25.68%	SMA50	-29.95%	SMA200	9.45%	Trades		Volume	1,476,276	Change	8.72%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Loading…
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks)
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
07:37AM	Loading…
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
07:29AM	Loading…
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)
Jun-06-23 06:50AM	Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study (Zacks)
Jun-05-23 11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)
Jun-01-23 03:29PM	Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company (Newsfile) +6.86%
May-30-23 09:35AM	Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP) (Zacks)
May-25-23 05:00PM	Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO (Newsfile)
May-12-23 07:29AM	Adaptimmune Reports First Quarter Financial Results and Business Update (Newsfile)
May-09-23 06:43AM	Is Adaptimmune Therapeutics (NASDAQ:ADAP) In A Good Position To Invest In Growth? (Simply Wall St.)
May-05-23 05:00AM	Zacks.com featured highlights Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth (Zacks)
Apr-28-23 12:00PM	Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023 (Newsfile)
Apr-18-23 11:49AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive But Perhaps Not Attractive Enough (Simply Wall St.)
Apr-12-23 10:42AM	Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK (Zacks)
Apr-11-23 12:13PM	Why Shares of Adaptimmune Therapeutics Jumped Tuesday (Motley Fool) +7.08%
08:00AM	Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune (Newsfile)
Mar-08-23 07:14AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:23AM	News Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts (Simply Wall St.)
Mar-06-23 01:08PM	Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company (Benzinga) -25.00%
06:30AM	Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update (Newsfile)
06:00AM	Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors (Newsfile)
Feb-22-23 08:00AM	Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023 (Newsfile)
Feb-16-23 08:00AM	Adaptimmune Announces Changes to Board of Directors (Newsfile)
Jan-09-23 08:00AM	Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma (Newsfile) -9.95%
Jan-08-23 07:06AM	Even after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years (Simply Wall St.)
Dec-28-22 06:51AM	Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day (Zacks) -5.30%
Dec-27-22 09:05AM	3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying (Zacks)
Dec-23-22 01:20PM	Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma (Newsfile)
Dec-10-22 09:02AM	Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses (Simply Wall St.)
Nov-18-22 08:00AM	Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent (Newsfile)
Nov-13-22 07:28AM	New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP) (Simply Wall St.)
Nov-11-22 10:52AM	Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing (American City Business Journals) +13.06%
Nov-10-22 06:03AM	Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) +5.71%
Nov-08-22 03:11PM	Why Adaptimmune Therapeutics Stock Is Glowing Green Today (Motley Fool) +25.30%
09:41AM	Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business (Simply Wall St.)
07:30AM	Adaptimmune Reports Third-Quarter Financial Results and Business Update (Newsfile)
07:00AM	Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers (Newsfile)
Oct-27-22 12:27PM	Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022 (Newsfile)
Oct-25-22 11:12AM	GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day (Benzinga) +5.83%
08:00AM	Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK (Newsfile)
Sep-09-22 10:23AM	Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers (Benzinga) -5.88%
07:00AM	Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors (Newsfile)
Aug-25-22 08:00AM	Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials (Newsfile)
Aug-10-22 06:27AM	Analysts Have Just Cut Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Revenue Estimates By 25% (Simply Wall St.)
Aug-04-22 07:30AM	Adaptimmune Reports Second-Quarter Financial Results and Business Update (Newsfile) +19.59%
Aug-01-22 06:21AM	Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) are in the red if they invested five years ago (Simply Wall St.) -5.95%
Jul-21-22 08:00AM	Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022 (Newsfile)
Jul-01-22 04:45PM	Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket (Motley Fool)
11:10AM	What Kind Of Investors Own Most Of Adaptimmune Therapeutics plc (NASDAQ:ADAP)? (Simply Wall St.)
Jun-27-22 03:27PM	Why Adaptimmune Therapeutics Stock Is Popping Today (Motley Fool)
Jun-01-22 10:17AM	We're Not Worried About Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn (Simply Wall St.)
May-26-22 05:00PM	Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track (Newsfile)
May-17-22 05:03PM	Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday (Motley Fool) +10.56%
May-16-22 05:00PM	Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT (GlobeNewswire)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '24	Sale	0.67	30,080	20,244	44,848	Jan 17 05:31 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '24	Sale	0.67	18,908	12,725	7,785	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 17 '24	Sale	0.67	18,276	12,300	7,785	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '24	Sale	0.67	18,114	12,191	7,785	Jan 17 05:30 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 16 '24	Sale	0.79	9,304	7,350	14,104	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Bertrand William C JR	Chief Operating Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 16 '24	Sale	0.79	2,287	1,807	3,363	Jan 17 05:31 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 12 '24	Sale	0.85	17,257	14,739	26,388	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 12 '24	Sale	0.85	7,799	6,661	11,841	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 11 '24	Sale	0.84	11,945	9,994	18,395	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Sep 01 '23	Sale	0.78	2,403	1,874	3,449	Sep 01 07:00 PM
Lunger John	Chief Patient Supply Officer	Aug 01 '23	Sale	0.91	3,096	2,804	4,718	Aug 01 05:00 PM
Menzel Garry E	Director	Jul 10 '23	Sale	0.91	47,702	43,447	75,056	Jul 10 05:01 PM
Rawcliffe Adrian	Chief Executive Officer	Jun 27 '23	Sale	0.92	2,333	2,146	3,519	Jun 27 09:15 PM

Open in Screener

LQDA

Liquidia Corp

Apr 19 • 04:00PM ET

13.29

Dollar change -0.52
Percentage change -3.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO DWAS VTWO PTH VHT IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	26.73%	Shs Outstand	68.63M	Perf Week	-4.73%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-0.53	Insider Trans	7.67%	Shs Float	55.70M	Perf Month	-16.42%
Income	-78.50M	PEG	-	EPS next Q	-0.32	Inst Own	47.14%	Short Float	13.34%	Perf Quarter	3.10%
Sales	17.49M	P/S	57.77	EPS this Y	5.30%	Inst Trans	-4.06%	Short Ratio	8.39	Perf Half Y	126.79%
Book/sh	0.69	P/B	19.29	EPS next Y	54.07%	ROA	-62.36%	Short Interest	7.43M	Perf Year	89.86%
Cash/sh	1.10	P/C	12.08	EPS next 5Y	-	ROE	-114.01%	52W Range	5.71 - 16.99	Perf YTD	10.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.44%	ROI	-158.09%	52W High	-21.78%	Beta	0.22
Dividend TTM	-	Quick Ratio	4.85	Sales past 5Y	423.30%	Gross Margin	76.18%	52W Low	132.75%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	4.85	EPS Y/Y TTM	-73.00%	Oper. Margin	-419.62%	RSI (14)	37.07	Volatility	5.34% 5.39%
Employees	136	Debt/Eq	0.07	Sales Y/Y TTM	9.75%	Profit Margin	-448.89%	Recom	1.57	Target Price	23.86
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-314.22%	Payout	-	Rel Volume	0.94	Prev Close	13.81
Sales Surprise	-4.30%	EPS Surprise	-81.66%	Sales Q/Q	-15.47%	Earnings	Mar 13 BMO	Avg Volume	885.56K	Price	13.29
SMA20	-11.45%	SMA50	-9.81%	SMA200	36.07%	Trades		Volume	829,328	Change	-3.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Apr-02-24 09:00AM	Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 06:00AM	Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Mar-20-24 01:50AM	Chief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA) (GuruFocus.com)
01:49AM	Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) (GuruFocus.com)
Mar-16-24 02:42PM	Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:54PM	Loading…
Mar-13-24 10:54PM	Q4 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) +5.36%
07:31AM	Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results (GuruFocus.com)
07:10AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 06:30AM	Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-21-24 03:17PM	United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings (Benzinga)
06:51AM	UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application (Reuters)
06:24AM	United Therapeutics, in unusual step, sues FDA over rivals drug application (BioPharma Dive)
Jan-30-24 06:30AM	Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-29-24 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet (Zacks)
06:25AM	Loading…
Jan-25-24 06:25AM	UPDATE 1-US FDA still reviewing Liquidia's inhaled blood pressure drug (Reuters)
06:00AM	Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Jan-19-24 06:30AM	Liquidia Corporation Announces Updates to Operations Leadership (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade (Zacks)
04:56PM	What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now? (Zacks)
Jan-08-24 08:22AM	Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims (GlobeNewswire)
Jan-05-24 06:45AM	Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD (GlobeNewswire)
Jan-04-24 09:10AM	Liquidia Corporation Announces $100 Million in New Financings (GlobeNewswire) +7.97%
Jan-02-24 06:45AM	Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-25-23 08:00AM	Biotech CEOs Are Buying Up Their Surging Stocks (Barrons.com)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:56PM	U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent) (GlobeNewswire) +35.70%
Dec-19-23 01:02PM	Insider Sell Alert: Chief Medical Officer Rajeev Saggar Sells 14,887 Shares of Liquidia Corp (LQDA) (GuruFocus.com) +5.63%
Dec-12-23 07:13AM	Liquidia Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
10:47AM	Loading…
Nov-08-23 10:47AM	Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:44AM	Q3 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 07:07AM	Liquidia Corp (LQDA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:30AM	Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 06:30AM	Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-02-23 07:00AM	Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors (GlobeNewswire)
Sep-25-23 04:09PM	FDA Accepts Submission to Add PH-ILD to YUTREPIA Label (GlobeNewswire)
Sep-06-23 04:30PM	United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office (GlobeNewswire)
Aug-13-23 05:22AM	Liquidia Corporation (NASDAQ:LQDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 12:38AM	Q2 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) -9.13%
Aug-10-23 07:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 08:17AM	Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-27-23 09:13AM	Liquidia Stock Down 12% But Insiders Still In US$74k Profit (Simply Wall St.)
06:00AM	Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Jul-25-23 02:37PM	Liquidia stock drops after setback in United Therapeutics dispute (American City Business Journals)
08:25AM	Silver Spring's United Therapeutics claims victory in patent infringement suit against Liquidia (American City Business Journals)
Jul-24-23 01:46PM	U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation (GlobeNewswire) -12.76%
Jun-29-23 11:24AM	Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug (Zacks) -17.68%
Jun-28-23 05:36AM	Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America (GlobeNewswire) +10.99%
May-31-23 06:30AM	Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 11:26AM	Investing in Liquidia (NASDAQ:LQDA) a year ago would have delivered you a 106% gain (Simply Wall St.)
May-21-23 03:39PM	Hero or Zero? 7 High-Risk Stocks to Make You Rich Or Broke. (InvestorPlace)
May-19-23 06:15AM	Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference (GlobeNewswire) +6.14%
May-09-23 06:33AM	Institutional investors are Liquidia Corporation's (NASDAQ:LQDA) biggest bettors and were rewarded after last week's US$60m market cap gain (Simply Wall St.)
May-04-23 09:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 06:45AM	Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-27-23 06:45AM	Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-20-23 04:17AM	Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength? (Zacks)
Apr-18-23 08:33AM	Liquidia Corporation's (NASDAQ:LQDA) Earnings Haven't Escaped The Attention Of Investors (Simply Wall St.)
Apr-11-23 06:45AM	Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 06:45AM	Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications (GlobeNewswire)
Mar-25-23 08:33AM	Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts (Simply Wall St.)
Mar-20-23 04:10AM	Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-18-23 08:34AM	Liquidia Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-17-23 03:22AM	Q4 2022 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 07:55AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.25%
06:30AM	Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-23 10:00AM	Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.41%
07:19AM	Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023 (GlobeNewswire)
Feb-17-23 07:33AM	Insiders saw their US$2.6m investment bump up to US$4.2m after Liquidia Corporation (NASDAQ:LQDA) soared 15% last week (Simply Wall St.)
Feb-05-23 08:49PM	Decision moves Liquidia, United Therapeutics patent dispute toward resolution (American City Business Journals)
Feb-03-23 05:10AM	Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength? (Zacks)
Feb-02-23 04:39PM	Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (793 Patent) (GlobeNewswire) +9.70%
06:30AM	Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 10:01PM	Liquidia inks $100M financing agreement amid patent dispute (American City Business Journals)
06:30AM	Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million (GlobeNewswire)
Dec-30-22 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Dec-14-22 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Dec-05-22 04:05PM	Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -5.65%
Dec-01-22 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet (Zacks) +5.78%
Nov-28-22 09:40AM	Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-08-22 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 10:15AM	ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS (PR Newswire)
Nov-01-22 06:45AM	Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) +5.93%
Oct-27-22 04:10PM	Precedential Opinion Panel Denies United Therapeutics Request for Review of 793 Inter Partes Review Decision (GlobeNewswire)
Oct-26-22 09:40AM	Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year? (Zacks)
Oct-17-22 06:30AM	Liquidia Announces Presentations at the CHEST 2022 Annual Meeting (GlobeNewswire)
Sep-26-22 06:45AM	7 Momentum Stocks to Buy Now for Extraordinary Gains (InvestorPlace)
Sep-10-22 08:24AM	Trade Alert: The CEO & Director Of Liquidia Corporation (NASDAQ:LQDA), Roger Jeffs, Has Just Spent US$244k Buying 2.6% More Shares (Simply Wall St.)
Sep-08-22 11:26AM	Liquidia (NASDAQ:LQDA) Is Using Debt Safely (Simply Wall St.) +5.87%
Sep-06-22 12:15PM	Liquidia faces delay for drug launch after ruling in United Therapeutics case (American City Business Journals)
Sep-02-22 05:58PM	Why Liquidia Stock Rocketed Nearly 21% Higher Today (Motley Fool) +20.58%
Aug-31-22 07:46PM	Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T. (GlobeNewswire) +7.25%
09:55AM	Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade (Zacks)
09:40AM	Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-23-22 03:09PM	Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen (Zacks)
12:00PM	Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy (Zacks)

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JEFFS ROGER	Chief Executive Officer	Apr 12 '24	Sale	14.58	8,360	121,889	826,985	Apr 16 05:15 PM
Kaseta Michael	CFO and COO	Apr 12 '24	Sale	14.58	3,136	45,723	315,045	Apr 16 05:16 PM
Schundler Russell	General Counsel	Apr 12 '24	Sale	14.58	2,060	30,035	486,027	Apr 16 05:17 PM
Moomaw Scott	Chief Commercial Officer	Apr 12 '24	Sale	14.58	1,585	23,109	151,881	Apr 16 05:16 PM
Saggar Rajeev	Chief Medical Officer	Apr 12 '24	Sale	14.58	1,525	22,234	213,321	Apr 16 05:17 PM
Adair Jason	Chief Business Officer	Apr 12 '24	Sale	14.58	1,189	17,336	111,537	Apr 15 08:31 PM
JEFFS ROGER	Chief Executive Officer	Mar 18 '24	Sale	15.82	28,583	452,183	835,345	Mar 19 09:46 PM
Kaseta Michael	CFO and COO	Mar 18 '24	Sale	15.82	12,166	192,466	318,181	Mar 19 09:47 PM
Schundler Russell	General Counsel	Mar 18 '24	Sale	15.82	8,653	136,890	488,087	Mar 19 09:48 PM
Saggar Rajeev	Chief Medical Officer	Mar 18 '24	Sale	15.82	7,530	119,125	214,846	Mar 19 09:46 PM
Moomaw Scott	Chief Commercial Officer	Mar 18 '24	Sale	15.82	6,108	96,629	153,466	Mar 19 09:47 PM
Adair Jason	Chief Business Officer	Mar 18 '24	Sale	15.81	4,657	73,649	108,640	Mar 19 09:50 PM
Moomaw Scott	Chief Commercial Officer	Feb 29 '24	Sale	14.17	546	7,737	159,574	Mar 04 07:07 PM
Adair Jason	Chief Business Officer	Feb 29 '24	Sale	14.17	455	6,447	97,412	Mar 04 07:05 PM
Adair Jason	Chief Business Officer	Dec 18 '23	Sale	7.70	77	593	54,932	Dec 20 05:20 PM
Caligan Partners LP	Director	Dec 14 '23	Buy	7.16	1,117,318	7,999,997	11,280,945	Dec 14 04:42 PM
Manning Paul B	Director	Dec 14 '23	Buy	7.16	279,330	2,000,003	279,330	Dec 18 05:00 PM
JEFFS ROGER	Chief Executive Officer	Dec 14 '23	Buy	7.16	139,665	1,000,001	640,805	Dec 18 05:02 PM
Moomaw Scott	Chief Commercial Officer	Nov 30 '23	Sale	7.28	542	3,946	106,737	Dec 05 09:18 PM
Lippe Robert A	Chief Operations Officer	Nov 30 '23	Sale	7.28	497	3,618	193,788	Dec 05 09:21 PM
Adair Jason	Chief Business Officer	Nov 30 '23	Sale	7.28	452	3,291	54,478	Dec 05 09:15 PM
Adair Jason	Chief Business Officer	Sep 19 '23	Sale	6.51	75	488	53,637	Sep 20 06:14 PM
Moomaw Scott	Chief Commercial Officer	Aug 31 '23	Sale	6.88	537	3,695	105,404	Sep 05 08:10 PM
Lippe Robert A	Chief Operations Officer	Aug 31 '23	Sale	6.88	505	3,474	192,567	Sep 05 08:11 PM
Adair Jason	Chief Business Officer	Aug 31 '23	Sale	6.88	445	3,062	53,452	Sep 05 08:09 PM
Moomaw Scott	Chief Commercial Officer	May 31 '23	Sale	8.08	651	5,260	102,268	Jun 02 05:05 PM
Lippe Robert A	Chief Operations Officer	May 31 '23	Sale	8.08	597	4,824	189,646	Jun 02 05:03 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ADAP

Adaptimmune Therapeutics Plc ADR

LQDA

Liquidia Corp

Upgrade your FINVIZ experience